Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Leukemia. 2014 Jun 20;29(2):346–355. doi: 10.1038/leu.2014.199

Figure 1.

Figure 1

OSU-2S mediates cytotoxicity in CLL primary cells. (a-c) Cytotoxic effects of OSU-2S in CLL. Freshly isolated CD19+ CLL primary cells (1×106/ml) were treated with OSU-2S (2µM) and viability was assessed 24 hours later. (a) Mixed CLL samples (N=25). (B-C) Activity of OSU-2S in prognostically poor CLL patient derived primary cells (b) IGVH unmutated (N=8) and (c) chromosome 17p deleted (N=5) CLL cells. (d) Comparison of OSU-2S and Fludarabine (2FaraA) cytotoxicity in CLL. CLL cells (10×106/ml) were treated with OUS-2S(8µM) or 2FaraA(10µM) and viability was measured at indicated time points (N=9). (e) OSU-2S activates PP2A. CLL cells treated with OSU-2S or FTY720 were used for an in-vitro PP2A phosphatase enzyme assay. Values were normalized to protein levels and vehicle treated control; bars represent SD (N=3).